출혈성/허혈성 뇌졸중 치료 기기 시장 규모, 점유율, 동향 분석 보고서 : 치료별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)

Hemorrhagic & Ischemic Stroke Treatment Devices Market Summary

The global hemorrhagic & ischemic stroke treatment devices market size was estimated at USD 3.80 billion in 2025 and is projected to reach USD 6.24 billion by 2033, growing at a CAGR of 6.42% from 2026 to 2033. The market is driven by the rising global burden of stroke, aging populations, and increasing prevalence of risk factors such as hypertension and diabetes.

Growing adoption of minimally invasive endovascular procedures, along with improvements in device safety, precision, and clinical outcomes, is accelerating demand. In addition, the expansion of comprehensive stroke centers and the development of faster treatment pathways are supporting the wider utilization of advanced stroke treatment technologies.

The rising incidence of hemorrhagic strokes is expected to significantly increase demand for hemorrhagic stroke treatment devices over the coming years. According to the Global Stroke Fact Sheet 2025 published by the World Stroke Organization, more than 12 million new stroke cases occur annually, and nearly one in four people worldwide will experience a stroke during their lifetime. The report indicates that intracerebral hemorrhage (ICH) accounts for 28.8% and subarachnoid hemorrhage (SAH) for 5.8% of all incident strokes, underscoring the substantial hemorrhagic stroke burden. The growing prevalence of this disease is anticipated to be a key factor supporting market growth during the forecast period.

The increasing focus on minimally invasive treatment strategies, including early minimally invasive evacuation of intracerebral hemorrhage (ICH) and endoscopic hematoma removal, is expected to be a key driver of market growth over the forecast period. Furthermore, ongoing clinical trials are supporting the development of technologies that improve procedural safety and clinical outcomes. For instance, in April 2024, NICO Corporation reported positive results from the ENRICH (Early MiNimally-invasive Removal of ICH) clinical trial, showing that early minimally invasive parafascicular surgery (MIPS) using its BrainPath and Myriad systems was safe and demonstrated superior outcomes compared with guideline-based medical management alone, the current standard of care for ICH.

The increasing volume of clinical trials conducted by research institutions, academic centers, and industry players is a key driver of the hemorrhagic stroke treatment devices market. These trials generate clinical evidence that validates the safety and effectiveness of minimally invasive and next-generation technologies, supporting regulatory approvals and clinician confidence. In addition, they facilitate innovation, expand treatment indications, and accelerate the adoption and commercialization of advanced devices, thereby driving sustained market growth.

The rapid advancement of neurovascular device technology is expected to play a crucial role in driving market expansion. Industry participants are focusing on developing and commercializing next-generation solutions that improve procedural accuracy, safety, and treatment effectiveness. In addition, innovations such as enhanced device design, improved materials, and better imaging compatibility are helping clinicians manage complex cases more efficiently, further supporting market growth.

Global Hemorrhagic & Ischemic Stroke Treatment Devices Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global hemorrhagic & ischemic stroke treatment devices market report based on treatment, end use, and region:

• Treatment Outlook (Revenue, USD Million, 2021 - 2033)
• Aneurysm & Hemorrhagic Stroke Interventions
  • By Indication
  • Intracranial Aneurysm
  • cSDH (MMA Embolization)
  • AVM & AVF Embolization
  • By Device
  • Embolization Coiling Systems
  • Bare Platinum Coils
  • Coated / Bioactive Coils
  • Flow Diversion Systems
  • Standard Flow-Diverting Stents (e.g., Pipeline)
  • Next-Generation / Surface-Modified Flow Diverters
  • Intrasaccular Flow Disruption Devices
  • Woven EndoBridge (WEB)
  • Contour Neurovascular System
  • Luna Aneurysm Embolization System
  • Liquid Embolization Agents
  • Non-Adhesive Liquid Embolics (Onyx, Squid, PHIL)
  • Adhesive Liquid Embolics (NBCA)
• Ischemic Stroke Interventions (Mechanical Revascularization)
  • Stent Retriever Systems
  • Aspiration-Based Thrombectomy Systems
• Cerebral Angioplasty & Vascular Remodeling
  • Balloon Angioplasty Systems
  • Intracranial & Carotid Stenting Systems
  • Coil-Assisted Adjunctive Devices (Balloon-assisted and stent-assisted)
• Ancillary & Procedural Access Devices
  • Guiding & Distal Access Catheters
  • Microcatheters
  • Access Sheaths & Wires
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Hospitals
• Specialty Neurosurgery Centers
• Ambulatory Surgical Centers
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Sweden
  • Denmark
  • Norway
  • Germany
  • UK
  • France
  • Italy
  • Spain
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
  • 1.1.1. Treatment
  • 1.1.2. End Use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Hemorrhagic & Ischemic Stroke Treatment Devices Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Drivers Analysis
    • 3.2.1.1. Rising burden of hemorrhagic stroke
    • 3.2.1.2. Growing focus on minimally invasive procedures
    • 3.2.1.3. Technological advancements in neurovascular devices
  • 3.2.2. Market Restraints Analysis
    • 3.2.2.1. High cost of devices and procedures
    • 3.2.2.2. Product recalls
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Growing emphasis on R&D expansion
    • 3.2.3.2. Rising public awareness about hemorrhagic stroke
    • 3.2.3.3. Increasing clinical trials
    • 3.2.3.4. Increasing launches of devices for ischemic stroke treatment
    • 3.2.3.5. Expansion opportunities in emerging markets
    • 3.2.3.6. Rising stroke incidence among younger adults
  • 3.2.4. Market Challenge Analysis
    • 3.2.4.1. Complications associated with neurovascular treatments
    • 3.2.4.2. Limited skilled professionals
• 3.3. Hemorrhagic & Ischemic Stroke Treatment Devices Market Analysis Tools
  • 3.3.1. Porter's Analysis
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social landscape
    • 3.3.2.3. Technological landscape
    • 3.3.2.4. Environmental landscape
    • 3.3.2.5. Legal landscape

Chapter 4. Hemorrhagic & Ischemic Stroke Treatment Devices Market: Treatment Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Hemorrhagic & Ischemic Stroke Treatment Devices Market: Treatment Movement Analysis, 2025 & 2033 (USD Million)
• 4.3. Global Hemorrhagic & Ischemic Stroke Treatment Devices Market Size & Trend Analysis, by Treatment, 2021 to 2033 (USD Million)
• 4.4. Aneurysm & Hemorrhagic Stroke Interventions
  • 4.4.1. Aneurysm & hemorrhagic stroke interventions market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. By indication
    • 4.4.2.1. By indication market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.2. Intracranial aneurysm
      • 4.4.2.2.1. Intracranial aneurysm market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.3. cSDH (MMA Embolization)
      • 4.4.2.3.1. cSDH (MMA Embolization) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.2.4. AVM & AVF embolization
      • 4.4.2.4.1. AVM & AVF embolization market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. By device
    • 4.4.3.1. By device market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.2. Embolization coiling systems
      • 4.4.3.1.1. Embolization coiling systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.2. Flow diversion systems
      • 4.4.3.2.1. Flow diversion systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.3. Intrasaccular flow disruption devices
      • 4.4.2.3.1. Intrasaccular flow disruption devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
    • 4.4.3.4. Liquid embolization agents
      • 4.4.3.4.1. Liquid embolization agents market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.5. Ischemic Stroke Interventions (Mechanical Revascularization)
  • 4.5.1. Ischemic stroke interventions (Mechanical Revascularization) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Stent retriever systems
    • 4.5.2.1. Stent retriever systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Aspiration-based thrombectomy systems
    • 4.5.3.1. Aspiration-based thrombectomy systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.6. Cerebral Angioplasty & Vascular Remodeling
  • 4.6.1. Cerebral angioplasty & vascular remodeling market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.2. Balloon angioplasty systems
    • 4.6.2.1. Balloon angioplasty systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.3. Intracranial & carotid stenting systems
    • 4.6.3.1. Intracranial & carotid stenting systems market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.6.4. Coil-assisted adjunctive devices (Balloon-assisted and stent-assisted)
    • 4.6.4.1. Coil-assisted adjunctive devices (Balloon-assisted and stent-assisted) market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 4.7. Ancillary & procedural access devices
  • 4.7.1. Ancillary & procedural access devices market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.2. Guiding & distal access catheters
    • 4.7.2.1. Guiding & distal access catheters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.3. Microcatheters
    • 4.7.3.1. Microcatheters market revenue estimates and forecasts, 2021 - 2033 (USD Million)
  • 4.7.4. Access sheaths & wires
    • 4.7.4.1. Access sheaths & wires market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 5. Hemorrhagic & Ischemic Stroke Treatment Devices Market: End Use Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Hemorrhagic & Ischemic Stroke Treatment Devices Market: End use Movement Analysis, 2025 & 2033 (USD Million)
• 5.3. Global Hemorrhagic & Ischemic Stroke Treatment Devices Market Size & Trend Analysis, by End use 2021 to 2033 (USD Million)
• 5.4. Hospitals
  • 5.4.1. Hospitals market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.5. Specialty Neurosurgery Centers
  • 5.5.1. Specialty neurosurgery centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)
• 5.6. Ambulatory Surgical Centers
  • 5.6.1. Ambulatory surgical centers market revenue estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 6. Hemorrhagic & Ischemic Stroke Treatment Devices Market: Regional Estimates & Trend Analysis by Treatment, and End Use

• 6.1. Regional Dashboard
• 6.2. Market Size and Trend Analysis, 2021 to 2033
• 6.3. North America
  • 6.3.1. North America hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.2. U.S.
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Competitive scenario
    • 6.3.2.3. Regulatory framework
    • 6.3.2.4. Reimbursement scenario
    • 6.3.2.5. U.S. hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.3. Canada
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Competitive scenario
    • 6.3.3.3. Regulatory framework
    • 6.3.3.4. Reimbursement scenario
    • 6.3.3.5. Canada hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.3.4. Mexico
    • 6.3.4.1. Key country dynamics
    • 6.3.4.2. Competitive scenario
    • 6.3.4.3. Regulatory framework
    • 6.3.4.4. Reimbursement scenario
    • 6.3.4.5. Mexico hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.4. Europe
  • 6.4.1. Europe hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.2. UK
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Competitive scenario
    • 6.4.2.3. Regulatory framework
    • 6.4.2.4. Reimbursement scenario
    • 6.4.2.5. UK hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.3. Germany
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Competitive scenario
    • 6.4.3.3. Regulatory framework
    • 6.4.3.4. Reimbursement scenario
    • 6.4.3.5. Germany hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.4. France
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Competitive scenario
    • 6.4.4.3. Regulatory framework
    • 6.4.4.4. Reimbursement scenario
    • 6.4.4.5. France hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.5. Italy
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Competitive scenario
    • 6.4.5.3. Regulatory framework
    • 6.4.5.4. Reimbursement scenario
    • 6.4.5.5. Italy hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.6. Spain
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Competitive scenario
    • 6.4.6.3. Regulatory framework
    • 6.4.6.4. Reimbursement scenario
    • 6.4.6.5. Spain hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Competitive scenario
    • 6.4.7.3. Regulatory framework
    • 6.4.7.4. Reimbursement scenario
    • 6.4.7.5. Sweden hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Competitive scenario
    • 6.4.8.3. Regulatory framework
    • 6.4.8.4. Reimbursement scenario
    • 6.4.8.5. Denmark hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.4.9. Norway
    • 6.4.9.1. Key country dynamics
    • 6.4.9.2. Competitive scenario
    • 6.4.9.3. Regulatory framework
    • 6.4.9.4. Reimbursement scenario
    • 6.4.9.5. Norway hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.5. Asia Pacific
  • 6.5.1. Asia Pacific hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Competitive scenario
    • 6.5.2.3. Regulatory framework
    • 6.5.2.4. Reimbursement scenario
    • 6.5.2.5. China hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.3. Japan
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Competitive scenario
    • 6.5.3.3. Regulatory framework
    • 6.5.3.4. Reimbursement scenario
    • 6.5.3.5. Japan hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.4. India
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Competitive scenario
    • 6.5.4.3. Regulatory framework
    • 6.5.4.4. Reimbursement scenario
    • 6.5.4.5. India hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Competitive scenario
    • 6.5.5.3. Regulatory framework
    • 6.5.5.4. Reimbursement scenario
    • 6.5.5.5. South Korea hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.6. Australia
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Competitive scenario
    • 6.5.6.3. Regulatory framework
    • 6.5.6.4. Reimbursement scenario
    • 6.5.6.5. Australia hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.5.7. Thailand
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Competitive scenario
    • 6.5.7.3. Regulatory framework
    • 6.5.7.4. Reimbursement scenario
    • 6.5.7.5. Thailand hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.6. Latin America
  • 6.6.1. Latin America hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6.2. Brazil
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Competitive scenario
    • 6.6.2.3. Regulatory framework
    • 6.6.2.4. Reimbursement scenario
    • 6.6.2.5. Brazil hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.6.3. Argentina
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Competitive scenario
    • 6.6.3.3. Regulatory framework
    • 6.6.3.4. Reimbursement scenario
    • 6.6.3.5. Argentina hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
• 6.7. Middle East and Africa
  • 6.7.1. Middle East and Africa hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.2. South Africa
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Competitive scenario
    • 6.7.2.3. Regulatory framework
    • 6.7.2.4. Reimbursement scenario
    • 6.7.2.5. South Africa hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.3. Saudi Arabia
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Competitive scenario
    • 6.7.3.3. Regulatory framework
    • 6.7.3.4. Reimbursement scenario
    • 6.7.3.5. Saudi Arabia hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.4. UAE
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Competitive scenario
    • 6.7.4.3. Regulatory framework
    • 6.7.4.4. Reimbursement scenario
    • 6.7.4.5. UAE hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)
  • 6.7.5. Kuwait
    • 6.7.5.1. Key country dynamics
    • 6.7.5.2. Competitive scenario
    • 6.7.5.3. Regulatory framework
    • 6.7.5.4. Reimbursement scenario
    • 6.7.5.5. Kuwait hemorrhagic & ischemic stroke treatment devices market estimates and forecasts, 2021 - 2033 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis by Key Market Participants
• 7.2. Company Categorization
• 7.3. Company Market Share Analysis, 2025
• 7.4. Company Heat Map Analysis
• 7.5. Strategy Mapping
  • 7.5.1. Expansion
  • 7.5.2. Mergers & Acquisition
  • 7.5.3. Partnerships & Collaborations
  • 7.5.4. New Treatment Launches
  • 7.5.5. Research And Development
  • 7.5.6. Company Profiles
  • 7.5.7. Medtronic
    • 7.5.7.1. Company overview
    • 7.5.7.2. Financial performance
    • 7.5.7.3. Treatment Benchmarking
    • 7.5.7.4. Strategic initiatives
  • 7.5.8. MicroVention, Inc. (Terumo Corporation)
    • 7.5.8.1. Company overview
    • 7.5.8.2. Financial performance
    • 7.5.8.3. Treatment Benchmarking
    • 7.5.8.4. Strategic initiatives
  • 7.5.9. Balt
    • 7.5.9.1. Company overview
    • 7.5.9.2. Financial performance
    • 7.5.9.3. Treatment Benchmarking
    • 7.5.9.4. Strategic initiatives
  • 7.5.10. Scientia Vascular, Inc.
    • 7.5.10.1. Company overview
    • 7.5.10.2. Financial performance
    • 7.5.10.3. Treatment Benchmarking
    • 7.5.10.4. Strategic initiatives
  • 7.5.11. MicroPort Scientific Corporation
    • 7.5.11.1. Company overview
    • 7.5.11.2. Financial performance
    • 7.5.11.3. Treatment Benchmarking
    • 7.5.11.4. Strategic initiatives
  • 7.5.12. Johnson & Johnson (MedTech)
    • 7.5.12.1. Company overview
    • 7.5.12.2. Financial performance
    • 7.5.12.3. Treatment Benchmarking
    • 7.5.12.4. Strategic initiatives
  • 7.5.13. phenox GmbH (Wallaby Medical)
    • 7.5.13.1. Company overview
    • 7.5.13.2. Financial performance
    • 7.5.13.3. Treatment Benchmarking
    • 7.5.13.4. Strategic initiatives
  • 7.5.14. Acandis GmbH
    • 7.5.14.1. Company overview
    • 7.5.14.2. Financial performance
    • 7.5.14.3. Treatment Benchmarking
    • 7.5.14.4. Strategic initiatives
  • 7.5.15. B. Braun SE
    • 7.5.15.1. Company overview
    • 7.5.15.2. Financial performance
    • 7.5.15.3. Treatment Benchmarking
    • 7.5.15.4. Strategic initiatives
  • 7.5.16. Integra LifeSciences
    • 7.5.16.1. Company overview
    • 7.5.16.2. Financial performance
    • 7.5.16.3. Treatment Benchmarking
    • 7.5.16.4. Strategic initiatives
  • 7.5.17. Infinity Neuro LLC
    • 7.5.17.1. Company overview
    • 7.5.17.2. Financial performance
    • 7.5.17.3. Treatment Benchmarking
    • 7.5.17.4. Strategic initiatives
  • 7.5.18. Penumbra, Inc.
    • 7.5.18.1. Company overview
    • 7.5.18.2. Financial performance
    • 7.5.18.3. Treatment Benchmarking
    • 7.5.18.4. Strategic initiatives
  • 7.5.19. Boston Scientific Corporation
    • 7.5.19.1. Company overview
    • 7.5.19.2. Financial performance
    • 7.5.19.3. Treatment Benchmarking
    • 7.5.19.4. Strategic initiatives
  • 7.5.20. Stryker
    • 7.5.20.1. Company overview
    • 7.5.20.2. Financial performance
    • 7.5.20.3. Treatment Benchmarking
    • 7.5.20.4. Strategic initiatives
  • 7.5.21. Peter LAZIC GmbH
    • 7.5.21.1. Company overview
    • 7.5.21.2. Financial performance
    • 7.5.21.3. Treatment Benchmarking
    • 7.5.21.4. Strategic initiatives
  • 7.5.22. Vesalio Inc.
    • 7.5.22.1. Company overview
    • 7.5.22.2. Financial performance
    • 7.5.22.3. Treatment Benchmarking
    • 7.5.22.4. Strategic initiatives